Immune booster shows promise for bipolar depression
NCT ID NCT04133233
First seen Apr 24, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This small study tested whether low-dose interleukin-2 (IL-2) could help people with bipolar disorder who are currently depressed. Fourteen participants already on mood stabilizers received the drug to see if it would improve their immune system's regulatory cells and ease depressive symptoms. The goal was to find a new way to treat bipolar depression without major side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pr Marion Leboyer
Créteil, Hôpital Albert Chenevier, 94010, France
Conditions
Explore the condition pages connected to this study.